5 5 9 0 6

论文已发表


注册即可获取德孚的最新动态



IF 收录期刊



更多详情 >>



作者优惠计划

Favored Author Program


很高兴为我们作者提供一种切实的方法以支持开放获取,并鼓励教师和研究人员通过开放获取模式,尽可能广泛地传播他们的作品。


作者优惠计划的成员将获得:


文章发表费(APC) 10% 的折扣


这 10% 的折扣从您加入 “作者优惠计划” 之时开始,并将适用于之后提交的所有论文



更多详情 >>



 

视频

Refinement of diagnosis and supporting evidence for the use of immunotherapy through sequential biopsies in a case of EML4-ALK positive lung cancer

 

Authors Song P, Zhang J, Zhang L

Received 28 January 2019

Accepted for publication 12 March 2019

Published 17 April 2019 Volume 2019:12 Pages 2943—2948

DOI https://doi.org/10.2147/OTT.S203192

Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Ms Aruna Narula

Peer reviewer comments 2

Editor who approved publication: Dr Tohru Yamada

Abstract: In this case report, we describe a tortuous, yet rare, treatment process of the patient. The first biopsy of the patient suggested inflammatory myofibroblastic tumor, ALK (D5F3) positive. Considering the benign progression of the disease, and no indication for surgical resection, oral prednisone was given first. However, the disease rapidly progressed, and a second biopsy revealed a pulmonary sarcomatoid cancer. Since the biopsy was ALK (D5F3) positive, the effect of crizotinib treatment was significant, though crizotinib resistance unfortunately only occurred after 4 months. The third biopsy pathology was performed and confirmed lung adenocarcinoma. After switching to pembrolizumab treatment, the lesions were significantly reduced after four courses of treatment. The current condition of patient persisted in partial response.
Keywords: sequential biopsies, EML4-ALK, immunotherapy, lung adenocarcinoma


 

摘要视频链接:Immunotherapy for ALK lung cancer